Clinical trials: Acquired Immunodeficiency Syndrome
Hiv
PrEPARE-SCALE: Scaling up Integrated PrEP Delivery in Kenyan Maternal and Child Health Clinics
This project aims to develop a community of practice; then test a combination of community of practice, quality improvement, and a training toolkit, to enhance implementation and clinical outcomes; and identify patterns…
- Trial name
- NCT06526507
- Testing
- Implementation strategy package
- Where
- 5 sites in Kenya
- Volunteers
- 17,000 people
- Sponsor
- University of Washington
HIV
CVCTPlus: A Couples-Based Approach to Linkage to Care and ARV Adherence
Men who have sex with men (MSM) continue to be the most heavily-impacted risk group in the US HIV epidemic. Studies suggest that the majority of incident HIV infections among MSM are attributable to sex with a main male sex…
- Trial name
- CVCTPLUS (NCT01772992)
- Testing
- CVCTPLUS
- Where
- 4 sites in United States
- Volunteers
- 586 people, healthy volunteers welcome
- Sponsor
- University of Michigan
HIV Infections
A Pharmacologically Guided Phase I/II Study of Daily Orally Administered Synthetic Hypericin in HIV-Infected Subjects
To determine the safety and tolerance of daily oral hypericin when given to achieve target trough levels within defined cohorts. To determine the responses of surrogate markers of HIV infection to daily oral hypericin.
- Trial name
- NCT00000792
- Testing
- Hypericin
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, Antiretroviral Therapy
Revised Simplified Algorithm for Treatment Eligibility for HIV (SLATEII)
In its 2017 revision of the global guidelines for HIV care and treatment, the World Health Organization called for rapid or same-day initiation of antiretroviral treatment (ART) for eligible patients testing positive for HIV.
- Trial name
- SLATEII (NCT03315013)
- Testing
- SLATE II
- Where
- South Africa
- Volunteers
- 600 people
- Sponsor
- Boston University
HIV Infections
Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV
Anti-HIV drug regimens have dramatically improved the rates of prevention of mother-to-child transmission (MTCT) of HIV in developed countries.
- Trial name
- NCT00270296
- Testing
- Trizivir, Lamivudine/Zidovudine, Lopinavir/Ritonavir
- Where
- 4 sites in Botswana
- Volunteers
- 730 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Seropositivity, Metabolic Syndrome
Effect on Liver Fat and Metabolic Parameters When Switching a Protease Inhibitor or Efavirenz to Raltegravir
This study will provide data on the switch from a protease inhibitor or efavirenz to the new formulation of raltegravir (RAL) dosed once daily.
- Conditions
- HIV Seropositivity, Metabolic Syndrome, Fatty Liver
- Trial name
- OBERAL (NCT03374358)
- Testing
- Raltegravir
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- Helsinki University Central Hospital
HIV-1 Infection
Novel Interventions in HIV-1 Infection
For several years there has been interest in why some people with HIV-1 progress more slowly to disease and have longer survival without Highly Active Antiretroviral Therapy (HAART) than others.
- Trial name
- IMIRC1003 (NCT01130376)
- Testing
- GTU-MultiHIV B clade vaccine1mg, Interleukin-2, GM-CSF
- Where
- United Kingdom
- Volunteers
- 12 people
- Sponsor
- Imperial College London
HIV, AIDS
Zinc Supplementation Effect on Immune Recovery in HIV Patients
INTRODUCTION: An adequate zinc supplementation is essential for a good immunological function. However, zinc deficiency is seen in more than 50% of adults infected with HIV.
- Conditions
- HIV, AIDS, Immunological Deficiency, Inadequate Immune Recovery
- Trial name
- NCT02162797
- Testing
- Zinc supplementation
- Where
- Colombia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CES University
HIV Infections
Indinavir Plus Efavirenz Plus Adefovir Dipivoxil in HIV-Infected Patients Who Have Not Had Success With Nelfinavir
The purpose of this study is to compare the effectiveness of giving indinavir plus efavirenz plus adefovir dipivoxil to patients who have failed treatment with nelfinavir and patients who have never taken a protease inhibitor…
- Trial name
- NCT00002220
- Testing
- Indinavir sulfate, Efavirenz, Levocarnitine
- Where
- 11 sites in United States
- Volunteers
- 120 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
A Multicenter, Double-Blind, Phase III, Adjuvant-Controlled Study of the Effect of 10 Units of HIV-1 Immunogen (Remune) Compared to Incomplete Freund's Adjuvant (IFA) Alone Every 12 Weeks on AIDS-Free Survival in Subjects With HIV Infection and CD4 T-Lymphocytes Between 300 and 549 Cells/microL Rega
To determine the effect of HIV-1 immunogen (Remune) on AIDS-free survival, defined as the time prior to development of an AIDS-defining condition or death.
- Trial name
- NCT00002359
- Testing
- HIV-1 Immunogen
- Where
- 54 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- The Immune Response Corporation
HIV Infection, Measles
Impact of HIV on Measles and Measles Immunisation
We conducted a longitudinal study to assess the immunogenicity of standard-titer measles vaccine in HIV-infected and uninfected Zambian children.
- Conditions
- HIV Infection, Measles, Children
- Trial name
- NCT00247091
- Testing
- standard-titer measles vaccine
- Where
- Zambia
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers
The purpose of the study is to determine the safety and tolerability of PRO 140, an investigational anti-HIV drug, administered via intravenous infusion.
- Trial name
- NCT00110591
- Testing
- PRO 140
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- CytoDyn, Inc.
Human Immunodeficiency Virus 1
A Study to Compare Brachial Artery Reactivity and Cardiovascular Risk of a Treatment Simplification by Darunavir/Ritonavir (DRV/r) 800/100 mg Versus a Triple Combination Therapy Containing DRV/r in HIV-1 Infected Patients
The purpose of this study is to compare change of brachial artery flow mediated vasodilatation using Darunavir/Ritonavir (DRV/r) 800/100 mg once daily as a monotherapy (use of a single medication) versus a triple combination…
- Trial name
- MONARCH (NCT01391013)
- Testing
- Darunavir(DRV), Ritonavir, 2 nucleoside reverse transcriptase inhibitors (NRTIs)
- Volunteers
- 30 people
- Sponsor
- Janssen-Cilag S.p.A.
HIV Infections
A Randomized Trial of the Efficacy and Safety of a Strategy of Starting With Nelfinavir Versus Ritonavir Added to Background Antiretroviral (AR) Nucleoside Therapy in HIV-Infected Individuals With CD4+ Cell Counts Less Than or Equal to 200/mm3
To compare nelfinavir (NFV) with ritonavir (RTV) for delaying disease progression or death in HIV-infected patients with CD4+ cell counts less than 100 cells/mm3 [AS PER AMENDMENT 3/11/98: less than or equal to 200 cells/mm3].
- Trial name
- NCT00000859
- Testing
- Indinavir sulfate, Ritonavir, Nelfinavir mesylate
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, HIV Seropositivity
Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia
COVID-19 has emerged as global pandemic during the past few months, with an unprecedented impact on public health, and society more generally.
- Conditions
- COVID-19, HIV Seropositivity, Tuberculosis, Pulmonary, Tuberculosis Infection
- Trial name
- Core-NB (NCT05268380)
- Testing
- Covid-19, TB and HIV diagnosis
- Where
- Namibia
- Volunteers
- 1,750 people
- Sponsor
- University of Namibia
Neoplasms, Squamous Cell, Papillomavirus Infections
Modeling Study to Predict Progression of Anal Cancer Pre-cursor Lesions in HIV
The purpose of this study is to determine whether a model can be created to predict the progression of early anal cancer precursor lesions in HIV using potential predictors such as: HIV treatment history, smoking history, sexual…
- Trial name
- NCT01709448
- Where
- 2 sites in United States
- Volunteers
- 165 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv
Joining Under-connected Networks to Optimize "Salud" (Health) ("JUNTOS")
The objective of this study is to evaluate the JUNTOS Referral Network as an implementation strategy to enhance the reach of HIV-prevention and treatment services to Latino gay, bisexual, and other men who have sex with men (MSM).
- Trial name
- NCT06432725
- Testing
- JUNTOS, Referral Sheet
- Where
- United States
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- University of Miami
HIV Infections, Syphilis Infection
Implementation of an Opt-Out Testing and Rapid Diagnostic Strategy for Syphilis and HIV in Pregnant Patients Presenting to the Emergency Department
The purpose of this study is to evaluate infection detection and treatment initiation rates for syphilis and HIV before and after integration of the Chembio DPP® HIV-Syphilis rapid POC test into an ongoing Emergency Department…
- Trial name
- NCT07525076
- Testing
- Chembio HIV/Syphilis rapid Point of Care (POC) test, Laboratory-based HIV and syphilis testing
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- The University of Texas Health Science Center, Houston
AIDS
Study To Investigate The Hemodynamic Effects Of Single Dose Vardenafil In Subjects Receiving Maraviroc
The objective of this study was to estimate the effects of a single dose of vardenafil on the blood pressure (BP) in subjects receiving maraviroc (MVC) (dosed to steady-state) and to assess the safety and tolerability of MVC in…
- Trial name
- NCT00853840
- Testing
- Maraviroc, Vardenafil
- Where
- Belgium
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Infections, HIV Seronegativity
A Study to Evaluate the Safety and Effectiveness of HIV-1 LAI gp120 (an HIV Vaccine) Given With or Without HIV-1 MN rgp120 (Another HIV Vaccine) to HIV-Negative Volunteers
The purpose of this study is to evaluate the safety and effectiveness of giving healthy volunteers a new oral HIV vaccine which has been incorporated into a bacterial cell.
- Trial name
- NCT00000868
- Testing
- Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203), Aluminum hydroxide, MF59
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.